Serum Albumin Level Can Predict Immunotherapy Response of Neuromyelitis Optica Spectrum Disorders in the Acute Phase
Weiwei Xiang,Yifan Wu,Hongyan Li,Desheng Zhu,Xiaoying Yao,Jie Ding,Ze Wang,Yangtai Guan
DOI: https://doi.org/10.2147/jir.s442532
IF: 4.5
2024-02-13
Journal of Inflammation Research
Abstract:Weiwei Xiang, 1, &ast Yifan Wu, 2, &ast Hongyan Li, 1, &ast Desheng Zhu, 1 Xiaoying Yao, 1 Jie Ding, 1 Ze Wang, 1 Yangtai Guan 1 1 Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 2 Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yangtai Guan, Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai, People's Republic of China, Email Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. However, few biomarkers have been found to predict the outcome of immunotherapy. We investigated the relationship between the serum albumin (S-Alb) and response to immunotherapy in acute NMOSD patients. Methods: A total of 107 consecutive Chinese patients with acute NMOSD diagnosed between January 2013 and January 2022 were included in our prospective observational study. S-Alb was measured by the use of bromocresol green and immunoturbidimetric methods on admission. The immunotherapy response was assessed by the percentage change in the expanded disability status scale (EDSS) score from admission to discharge after treatment. We evaluated the association between S-Alb and immunotherapy response through multivariate logistic regression analysis. Results: S-Alb levels were significantly lower in patients who were resistant to immunotherapy than in those who were responsive to treatment ( p < 0.001). S-Alb levels were positively related to a favorable response to immunotherapy ( r =0.386, p < 0.001). The odds ratio (95% CI) for the association between S-Alb level and response to immunotherapy was 1.27 (95% CI=1.08, 1.50; p =0.004) after adjusting for potential factors. ROC analysis showed that patients with S-Alb levels lower than 40.85 g/L were likely to be resistant to immunotherapy. Conclusion: Our study indicated that a higher S-Alb was an independent indicator of response to immunotherapy in acute NMOSD patients. Keywords: immune diseases, NMOSD, immunotherapy, albumin, multivariate analysis Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system, which is characterized by recurrent longitudinal extensive myelitis (LETM) and optical neuritis (ON). 1,2 NMOSD was once thought to be a subtype of multiple sclerosis (MS). Since the discovery of immunoglobulin against aquaporin-4 (also known as AQP4-lgG), a water channel mainly located on astrocytes in the brain, NMOSD has been confirmed to be a distinct entity. 3 Acute attacks can cause severe morbidity or can even be fatal. Therefore, reducing the severity of acute attacks in NMOSD patients is essential. The most common treatment for acute NMOSD is a high-dose corticosteroid, typically intravenous methylprednisolone (IVMP). 4 Intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) are also treatment choices for patients who respond poorly to the steroid therapy. 2,4 Only few studies have evaluated clinical factors that may be related to a favorable outcome of treatment with PLEX, such as a short-delay to initiation and a less severe attack. 5–7 However, few biomarkers have been found to predict the outcome of immunotherapy. Serum albumin (S-Alb) is an inherent drug delivery platform with a long circulatory half-life. 8 Recent studies have revealed its neuroprotective effects, such as acting as a target for oxidation and nitration reactions and reducing the production of reactive oxygen and reactive nitrogen species in the CNS. 9 Clinically, S-Alb is a prognostic factor in various autoimmune diseases in the CNS, such as autoimmune encephalitis 10 and Guillain–Barré syndrome (GBS). 11 We hypothesized that S-Alb levels may be a predictor of the response to immunotherapy in acute NMOSD patients. In this study, we aimed to determine the serum level of albumin in patients with NMOSD and its association with the outcome of immunotherapy in the acute phase. This was a prospective observational study designed to explore the relationship between the S-Alb and immunotherapy response in acute NMOSD patients. Consecutive patients were enrolled in our study from Renji Hospital in China from January 2013 to January 2022, and patient data were recorded in the NMOSD Registry Database of the hospital. The cerebrospinal fluid (C -Abstract Truncated-
immunology